-

Axial Biotherapeutics to Present at the Chardan 2nd Annual Microbiome Medicines Virtual Summit

WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a virtual company overview and participate in a virtual panel on “Modulating the Microbiome” at the Chardan 2nd Annual Microbiome Medicines Summit on Monday, March 16, 2020 at 8:45 AM ET and 12:40 PM ET, respectively.

A recording of the presentation and panel can be accessed at http://bit.ly/2v8qwB1.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease (PD) and Autism Spectrum Disorder (ASD).

Contacts

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com

Industry:

Axial Biotherapeutics

Release Versions
English

Contacts

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com

More News From Axial Biotherapeutics

Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET. About Axial Biotherapeutics Axial Biotherapeuti...

Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the upcoming virtual presentation on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting being held May 29-30, 2020. Virtual...

Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder

WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced positive topline data from its Phase 1b/2a clinical trial of AB-2004, a first-in-class therapeutic that removes certain metabolites from the gastrointestinal (GI) tract for the treatment of Autism Spectrum Disorder (ASD). The study met the primary endpoint of safety, tolerabi...
Back to Newsroom